Literature DB >> 1585854

Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men.

G Sigurdsson1, A Baldursdottir, H Sigvaldason, U Agnarsson, G Thorgeirsson, N Sigfusson.   

Abstract

Some studies have suggested that measurements of apolipoproteins may be valuable in the clinical assessment of susceptibility to coronary artery disease, over and above the lipoprotein lipids. Only a few of these studies have been prospective in nature and further knowledge is therefore needed to clarify the issue. The independent prognostic value of apolipoproteins (apo-B, apo-AI and apo[a]) with regard to coronary artery disease was estimated from a prospective survey among 1,332 randomly selected Icelandic men, aged 45 to 72 years, participating in a health survey from 1979 to 1981. The group was followed for 8.6 years, and during that period 104 men had fatal or nonfatal myocardial infarction. The Cox's proportional hazards model was used to estimate the significance of independent variables. The results of multivariate analysis showed that apo(a) was a significant independent risk factor (odds ratio 1.22 for 1 SD), but apo-AI was a stronger negative risk factor (odds ratio 0.70 for 1 SD). Apo-B was a highly significant risk factor in a univariate analysis, but not in a multivariate analysis when serum cholesterol was included. Previous population surveys in Iceland have confirmed the importance of cigarette smoking, cholesterol, triglycerides and blood pressure as risk factors for coronary artery disease. The present results illustrate additional importance of apo-AI and apo(a) concentrations in predicting coronary artery disease among Icelandic men, whereas apo-B did not contribute anything further to the prediction than serum total cholesterol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585854     DOI: 10.1016/0002-9149(92)91215-p

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Novel markers of inflammation in atherosclerosis.

Authors:  Salim S Virani; Venkateshwar R Polsani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

2.  High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coronary artery bypass graft surgery.

Authors:  J S Skinner; M Farrer; C J Albers; H A Neil; P C Adams
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

3.  A unique pattern of apo(a) polymorphism in an isolated east Greenlandic Inuit (Eskimo) population.

Authors:  I C Klausen; P S Hansen; J V Povlsen; L U Gerdes; L Lemming; O Faergeman
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

4.  The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

Authors:  D J Rader; W Cain; K Ikewaki; G Talley; L A Zech; D Usher; H B Brewer
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  The evaluation of carotid intima-media thickness in children with familial Mediterranean fever.

Authors:  Harun Peru; Bülent Altun; Mustafa Doğan; Fatih Kara; Ahmet Midhat Elmaci; Bülent Oran
Journal:  Clin Rheumatol       Date:  2007-10-10       Impact factor: 2.980

6.  Correlation analysis between serum lipoprotein (a) and the incidence of aortic valve sclerosis.

Authors:  Ning Yang; Guogang Zhang; Xiaogang Li; Liping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events.

Authors:  Jacqueline Suk Danik; Nader Rifai; Julie E Buring; Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2008-07-08       Impact factor: 24.094

8.  Comparative study of risk factors in patients undergoing coronary or femoropopliteal artery bypass grafting.

Authors:  F Mainard; J L Auget; P Vest; Y Madec
Journal:  Br Heart J       Date:  1994-12

9.  Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein (a) size polymorphism.

Authors:  H G Kraft; C Haibach; A Lingenhel; C Brunner; M Trommsdorff; F Kronenberg; H J Müller; G Utermann
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

10.  The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.

Authors:  J Danesh; S Erqou; M Walker; S G Thompson; R Tipping; C Ford; S Pressel; G Walldius; I Jungner; A R Folsom; L E Chambless; M Knuiman; P H Whincup; S G Wannamethee; R W Morris; J Willeit; S Kiechl; P Santer; A Mayr; N Wald; S Ebrahim; D A Lawlor; J W G Yarnell; J Gallacher; E Casiglia; V Tikhonoff; P J Nietert; S E Sutherland; D L Bachman; J E Keil; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; B G Nordestgaard; R Frikke-Schmidt; S Giampaoli; L Palmieri; S Panico; D Vanuzzo; L Pilotto; L Simons; J McCallum; Y Friedlander; F G R Fowkes; A J Lee; F B Smith; J Taylor; J Guralnik; C Phillips; R Wallace; D Blazer; K T Khaw; J H Jansson; C Donfrancesco; V Salomaa; K Harald; P Jousilahti; E Vartiainen; M Woodward; R B D'Agostino; P A Wolf; R S Vasan; M J Pencina; E M Bladbjerg; T Jorgensen; L Moller; J Jespersen; R Dankner; A Chetrit; F Lubin; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; C Bjorkelund; P Cremer; D Nagel; R Tilvis; T Strandberg; B Rodriguez; L M Bouter; R J Heine; J M Dekker; G Nijpels; C D A Stehouwer; E Rimm; J Pai; S Sato; H Iso; A Kitamura; H Noda; U Goldbourt; V Salomaa; J T Salonen; K Nyyssönen; T-P Tuomainen; D Deeg; J L Poppelaars; T Meade; J Cooper; B Hedblad; G Berglund; G Engstrom; A Döring; W Koenig; C Meisinger; W Mraz; L Kuller; R Selmer; A Tverdal; W Nystad; R Gillum; M Mussolino; S Hankinson; J Manson; B De Stavola; C Knottenbelt; J A Cooper; K A Bauer; R D Rosenberg; S Sato; Y Naito; I Holme; H Nakagawa; H Miura; P Ducimetiere; X Jouven; C Crespo; M Garcia-Palmieri; P Amouyel; D Arveiler; A Evans; J Ferrieres; H Schulte; G Assmann; J Shepherd; C Packard; N Sattar; B Cantin; B Lamarche; J-P Després; G R Dagenais; E Barrett-Connor; D Wingard; R Bettencourt; V Gudnason; T Aspelund; G Sigurdsson; B Thorsson; M Trevisan; J Witteman; I Kardys; M Breteler; A Hofman; H Tunstall-Pedoe; R Tavendale; G D O Lowe; Y Ben-Shlomo; B V Howard; Y Zhang; L Best; J Umans; A Onat; T W Meade; I Njolstad; E Mathiesen; M L Lochen; T Wilsgaard; J M Gaziano; M Stampfer; P Ridker; H Ulmer; G Diem; H Concin; F Rodeghiero; A Tosetto; E Brunner; M Shipley; J Buring; S M Cobbe; I Ford; M Robertson; Y He; A M Ibanez; E J M Feskens; D Kromhout; R Collins; E Di Angelantonio; S Kaptoge; S Lewington; L Orfei; L Pennells; P Perry; K Ray; N Sarwar; M Scherman; A Thompson; S Watson; F Wensley; I R White; A M Wood
Journal:  Eur J Epidemiol       Date:  2007-09-18       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.